Cargando…
Novel tricyclic pyrazole BRAF inhibitors with imidazole or furan central scaffolds
V-RAF murine sarcoma viral oncogene homolog B1 (BRAF) is a serine/threonine-specific protein kinase that is mutated with high frequency in cutaneous melanoma, and many other cancers. Inhibition of mutant BRAF is an attractive therapeutic approach for the treatment of melanoma. A triarylimidazole BRA...
Autores principales: | Niculescu-Duvaz, Dan, Niculescu-Duvaz, Ion, Suijkerbuijk, Bart M.J.M., Ménard, Delphine, Zambon, Alfonso, Nourry, Arnaud, Davies, Lawrence, Manne, Helen A., Friedlos, Frank, Ogilvie, Lesley, Hedley, Douglas, Takle, Andrew K., Wilson, David M., Pons, Jean-Francois, Coulter, Tom, Kirk, Ruth, Cantarino, Neus, Whittaker, Steven, Marais, Richard, Springer, Caroline J. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Elsevier Science
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956513/ https://www.ncbi.nlm.nih.gov/pubmed/20667740 http://dx.doi.org/10.1016/j.bmc.2010.06.031 |
Ejemplares similares
-
The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers
por: Saturno, G., et al.
Publicado: (2021) -
Toward the Scale-Up of a Bicyclic Homopiperazine via
Schmidt Rearrangement and Photochemical Oxaziridine Rearrangement
in Continuous-Flow
por: Brown, Michael, et al.
Publicado: (2020) -
Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma
por: Girotti, Maria Romina, et al.
Publicado: (2015) -
Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma
por: Girotti, Maria Romina, et al.
Publicado: (2017) -
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
por: Heidorn, Sonja J., et al.
Publicado: (2010)